THE DAC PLATFORM
Our Science
Discover how TriCore combines antibody-directed delivery with targeted protein degradation to develop new cancer therapeutics.
THE NEXT FRONTIER
Targeted protein degradation
Targeted protein degradation uses the cell’s own protein-disposal machinery to remove disease-driving proteins. It can open new routes to cancer targets that are difficult to address with conventional inhibitors.
CONVENTIONAL INHIBITORS
- Bind to a protein to inhibit its activity.
- Occupancy-driven: effect depends on sustained target binding.
- Leave the target protein in the cell.
TARGETED PROTEIN DEGRADATION
- Uses the cell’s machinery to remove a target protein.
- Event-driven: a degrader molecule can trigger protein removal and then act again.
- Can address some proteins that are difficult to inhibit.
ANTIBODY-DIRECTED DELIVERY
Degrader-antibody conjugates
Systemically delivered degraders face challenges when their targets are also present in healthy tissue. Their size and chemical properties can also make effective drug delivery difficult.
Degrader-antibody conjugates pair an antibody with a protein-degrading payload. Antibody-directed delivery can help address these challenges by carrying the payload to selected cells. TriCore brings a modular approach to developing these therapeutics.
Why TriCore
TriCore combines antibody-directed delivery with a modular approach to targeted protein degradation. The platform supports DAC development across a broad range of cancer targets.
Early laboratory studies have demonstrated target engagement and protein degradation. These findings support further preclinical evaluation of TriCore-based DACs.
Our initial focus is aggressive solid tumors. Current development is directed toward evaluating DAC candidates and generating the evidence needed to select a lead development candidate.
Get in touch
Contact 3C Therapeutics to discuss investment, partnering opportunities or scientific collaborations.